<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess efficacy and safety of saxagliptin added to <z:chebi fb="0" ids="6801">metformin</z:chebi> versus placebo plus <z:chebi fb="0" ids="6801">metformin</z:chebi> in Asian patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and inadequate glycemic control on <z:chebi fb="0" ids="6801">metformin</z:chebi> alone </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Adults (HbA(1c) 7.0-10.0%, on stable <z:chebi fb="0" ids="6801">metformin</z:chebi> ≥ 1500 mg/day) were randomized 1:1 to saxagliptin 5mg daily plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (n = 283) or placebo plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (n = 287) </plain></SENT>
<SENT sid="2" pm="."><plain>The primary end point was HbA(1c) change from baseline to Week 24 </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Saxagliptin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> provided significant adjusted mean decreases versus placebo plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (p ≤ 0.0052) in HbA(1c) (-0.78% versus -0.37%), fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (-1.14 mmol/L versus -0.58 mmol/L), and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> area under the curve from 0 to 180 min (-315 mmol min/L versus -160 mmol min/L) </plain></SENT>
<SENT sid="4" pm="."><plain>Significantly more saxagliptin-treated patients achieved a therapeutic glycemic response (HbA(1c)&lt;7.0%) (46.5% versus 30.5%; p = 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>The proportion of patients experiencing adverse events (excluding <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>) was similar for saxagliptin plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (42.8%) versus placebo plus <z:chebi fb="0" ids="6801">metformin</z:chebi> (40.8%) </plain></SENT>
<SENT sid="6" pm="."><plain>Hypoglycemic events were reported in 1.4% of patients in each group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Saxagliptin added to <z:chebi fb="0" ids="6801">metformin</z:chebi> significantly improved glycemic control and was well tolerated in Asian patients with T2DM who had inadequate glycemic control with <z:chebi fb="0" ids="6801">metformin</z:chebi> and diet and lifestyle modification </plain></SENT>
</text></document>